Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease. by Mitja, Jevnikar et al.
Respiratory muscle training with enzyme replacement therapy improves
muscle strength in late - onset Pompe disease
Jevnikar Mitja a,⁎, Kodric Metka a, Cantarutti Fabiana a, Rossella Cifaldi a, Cinzia Longo a, Della Porta Rossana a,
Bembi Bruno b, Confalonieri Marco a
a Department of Pneumology, University Hospital of Cattinara, Trieste, Italy
b Rare Diseases Regional Centre, University Hospital “S. Maria della Misericordia”, Udine, Italy
a b s t r a c ta r t i c l e i n f o
Article history:
Received 25 July 2015
Received in revised form 30 September 2015
Accepted 30 September 2015
Available online 29 October 2015
Keywords:
Pompe disease
Late-onset type II glycogenosis
Respiratory muscles
Muscle training
Enzyme replacement therapy
Background: Pompe disease is an autosomal recessive metabolic disorder caused by the deﬁciency of the lyso-
somal enzyme acidα-glucosidase. This deﬁciency leads to glycogen accumulation in the lysosomes ofmuscle tis-
sue causing progressivemuscular weakness particularly of the respiratory system. Enzyme replacement therapy
(ERT) has demonstrated efﬁcacy in slowing down disease progression in infants. Despite the large number of
studies describing the effects of physical training in juvenile and adult late onset Pompe disease (LOPD). There
are very few reports that analyze the beneﬁts of respiratory muscle rehabilitation or training.
Methods: The effectiveness of respiratorymuscle trainingwas investigated using a speciﬁc appliancewith adjust-
able resistance (Threshold). The primary endpointwas effect on respiratorymuscular strength bymeasurements
ofMIP andMEP. Eight late-onset Pompe patients (aged 13 to 58 years; 4 female, 4male) with respiratorymuscle
deﬁciency on functional respiratory tests were studied. All patients received ERT at the dosage of 20mg/kg/every
2 weeks and underwent training with Threshold at speciﬁed pressures for 24 months.
Results: A signiﬁcant increase in MIP was observed during the follow-up of 24 month: 39.6 cm H2O (+25.0%) at
month 3; 39.5 cm H2O (+24.9%) at month 6; 39.1 cm H2O (+23.7%) at month 9; 37.3 cm H2O (+18.2%) at
month 12; and 37.3 cmH2O (+17.8%) atmonth 24.MedianMEP values also showed a signiﬁcant increase during
the ﬁrst 9 months: 29.8 cm H2O, (+14.3%) at month 3; 31.0 cm H2O (+18.6) at month 6; and 29.5 cm H2O
(+12.9) at month 9. MEP was then shown to be decreased at months 12 and 24; median MEP was 27.2 cm
H2O (+4.3%) at 12months and 26.6 cmH2O (+1.9%) at 24months. The FVC remain stable throughout the study.
Conclusion: An increase in respiratory muscular strength was demonstrated with Threshold training when used
in combination with ERT.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Pompe disease is an inherited autosomal recessive disorder caused
by the deﬁciency of the enzyme acid α-glucosidase (GAA), which
leads to an intralysosomal accumulation of glycogen in various tissues,
especially skeletal muscle [1]. The disease occurs in approximately 1
per 40,000 births and causes a progressive myopathy. Based on the
time of symptom development, the disease is typically classiﬁed as
early-infantile onset (IOPD) with absence or nearly loss of GAA activity
resulting in cardiomyopathy and muscle hypotonia and poor prognosis
without therapy or late-onset childhood, juvenile or adult form (LOPD).
The late-onset type usually involves the proximal muscles and the re-
spiratory muscles with progressive respiratory muscle weakness,
night-time respiratory difﬁculty, progressive hypoventilation, as well
as abnormal laboratory data including polycythemia, rise of carbon di-
oxide (pCO2) in blood, thus potentially leading to respiratory failure
[2]. In some cases, respiratory insufﬁciency may be present without
limb-girdle muscle weakness [3]. The degree of involvement of respira-
tory muscles is evaluated by pulmonary function tests (forced vital ca-
pacity [FVC], maximum inspiratory pressure [MIP], and maximum
expiratory pressure [MEP]), sleep assessment, and blood gas analysis
[4]. The main treatment option is enzyme replacement therapy (ERT)
[5,6]. Guidelines for physiotherapeutic management of muscular respi-
ratory weakness are not available; however, current recommendations
suggest following the guidelines of other neuromuscular disorders [7] in
order to maintainmuscular and respiratory function, prevent complica-
tions and preserve the highest level of autonomy. Studies on muscle
training and rehabilitation in patients with Pompe disease recommend
aerobic and sub-maximal exercise to stimulate the degradation of the
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glycogen accumulated in cytosol [8]. Maximal muscular exercise is con-
sidered dangerous because it could lead to greater muscle degeneration
[9]. Training protocols for neuromuscular diseases have been proposed
since disease-speciﬁc programs are lacking. These procedures require
the use of sub-maximal and aerobic exercise to avoid excessive work
and to take advantage of functional activities; cardiopulmonary re-
sponse should also be monitored [10]. The potential beneﬁts of pulmo-
nary rehabilitation or training of respiratory muscles in late onset
Pompe disease are not yet known. There is only a single report available
of respiratory muscle training showing an improvement in expiratory
and inspiratory strength after a short training period [11].
2. Methods
We performed a longitudinal, observational study that was approved
by the Ethics Committee of the Hospital of Cattinara (Trieste, Italy) and
conducted between March 2007 and November 2011 all eight patients
completed the study protocol of 24 months of training. This study aims
at evaluating the effectiveness of inspiratory muscle training using a spe-
ciﬁc device with adjustable resistance (Threshold, Respironics, Inc.,
below: threshold) in patients with late-onset Pompe disease (LOPD) re-
ceiving ERT. The study included 8 patients and the inclusion criteria
were diagnosis with LOPD, determined by lack of GAA enzyme activity
performed on skin ﬁbroblasts (the gold standard for Pompe disease diag-
nosis) and muscular weakness on pulmonary function tests. All patients
were treated with ERT for at least one year before the beginning of the
study. No comorbidities except a diagnosis of asthma were present in
one patient in the study group. This criterion was included in order to
be sure that the improvement inmuscle strengthwas due to the training
protocol, and not ERT. Patients were required to have a degree of auton-
omy between Grades 4 and 5 on themodiﬁed Gardner–Medwin–Walton
scale. Exclusion criteria included respiratory failure and lack treatment
with ERT. Follow-up visits were scheduled at 3, 6, 9, 12 and 24 months.
Pulmonary function tests and respiratorymuscle strengthwere evaluated
at each visit, particularly the maximal inspiratory pressure (MIP), mea-
sured at residual volume, and the maximal expiratory pressure (MEP),
measured from total lung capacity. All measurements were performed
with the device―Micro MPM 8 (Micro Medical Limited, Rochester, En-
gland). Forced vital capacity (FVC) in sitting position and clinical exami-
nation using the modiﬁed Gardner–Medwin–Walton scale to determine
the grade of autonomy were also evaluated.
2.1. Training device
The threshold is a device that exerts training of the inspiratory mus-
cles against ﬁxed resistance based on the technique developed by
Nickerson and Keens [12]. In this disease training with threshold has
been recommended because of its ability to maintain a constant resis-
tance regardless of breathing rate. The positive effects of inspiratory
muscle trainingwith threshold are recognized in obstructive pulmonary
diseases [13,14,15], myasthenia gravis [16], amyotrophic lateral sclero-
sis [17], diaphragmatic dysfunction [18], congestive heart failure [19], as
well as patients weaned from mechanical ventilation [20].
2.2. Training protocol
At the ﬁrst visit, patients were instructed to perform the training
protocol with medical and physiotherapy supervision. In the case of pe-
diatric patients, the family and parentswere also educated on the proto-
col. The following was used for the threshold training protocol:
Training cycle: 1′ inspiratory load set at 30% of best MIP, followed by
2′ deep slow breathing. The patient was instructed to perform 15 train-
ing cycles per day for 45min (15′ at 30% ofMIP and 30′ at rest with deep
slow breathing) 7 days/week.
Inspiratory load varied according to the MIP percentage at each con-
trol visit. The load was adjusted according to the most recent, highest
MIP measure. If 30% of best MIP was below the minimum load available
for the threshold, the device was regulated at the minimum value. How-
ever, the patient was asked to initially maintain the training load for 30″,
with the same resting period. If the MIP increased during training, an
increase in workload was added to obtain the 30% of the best MIP. Com-
pliance with the training protocol was evaluated under medical supervi-
sion on each control visit with the presence of the physiotherapist. The
patients were interviewed weekly between control visits to check and
support the compliance at home. Furthermore, proper use of the thresh-
old was evaluated during each administration of ERT. The primary end-
point was to determine the efﬁcacy of the training by improvement in
MIP aswell as pulmonary function tests at each control visit. Standard de-
scriptive statistics were used to analyze the demographic and clinical
characteristics of the patients at baseline. The One Way repeated mea-
sures ANOVA with the Sigma Stat program was used to compare MIP,
MEP, and FVC from baseline to 3, 6, 9, 12 and 24 months. A two-tailed p
value b0.05 was considered signiﬁcant.
3. Results
Between March 2007 and November 2011 all eight patients com-
pleted the study protocol of 24months of training. All patients were re-
ceiving ERT during the study and none were on ventilatory support or
bedridden. The demographic and clinical characteristics of the 8 pa-
tients at baseline are shown in Table 1. show the values of MIP, MEP,
and FVC measured at baseline and at follow-up visits for each patient.
3.1. Pulmonary function
At baseline, the mean (SD) MIP was 31.6 cm H2O (SD: ±17.7). The
average improvement from baseline in MIP at 3 months (mean:
39.6 cm H2O [SD: 20.5]) was +25.2%, at 6 months (mean: 39.5 cm
H2O; [SD: ±20.5]) was +24.9%, at 9 months (mean: 39.1 cm H2O
[SD: ±20.1]) was +23.7%, at 12 months (mean 37.3 cm H2O;
[SD: ±19.6]) was +18.2%, and at 24 months (mean: 37.2 cm H2O;
[SD: ±19.3]) was +17.8% in our group of patients (Fig. 1).
The difference inMIP between baseline and follow-up visits was sta-
tistically signiﬁcant (p 0008). At 3 and 24 months, MIP values were
Table 1
Values of MIP, MEP and FVC measured at baseline and at follow-up visits.
Patient PFT 6–8
months
before
Baseline 3
months
6
months
9
months
12
months
24
months
1 MIP 50 50 53 51 55 50 47
MEP 44 43 49 46 47 46 48
FVC 79 79 81 78 76 80 88
2 MIP 22 12 17 15 14 15 18
MEP 30 10 12 13 12 10 10
FVC 33 32 31 30 29 27 27
3 MIP 61 12 15 16 19 15 14
MEP 70 13 14 15 18 19 17
FVC 48 42 46 43 41 38 40
4 MIP 34 30 35 33 32 31 35
MEP 40 18 24 26 20 21 26
FVC 81 86 75 88 83 80 92
5 MIP 30 63 74 74 73 70 74
MEP 48 43 51 49 48 45 38
FVC 62 51 65 60 55 58 57
6 MIP 36 35 58 59 55 56 50
MEP 68 41 48 49 45 43 41
FVC 25 23 25 21 17 19 21
7 MIP 33 24 29 33 35 31 31
MEP 62 24 21 29 26 15 12
FVC 30 23 29 20 25 24 28
8 MIP 28 27 36 35 30 31 29
MEP 34 17 20 21 20 19 21
FVC 40 35 37 32 34 31 30
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comparable, demonstrating that the improvement remained stable over
the course of the study (p b 0.05; Table 5). MEP was also evaluated. At
baseline, the mean (SD) were 26.1 cmH2O (SD: ±14). There was a sta-
tistically signiﬁcant increase in MEP from baseline at 3 months by
+14.3% (mean: 29.8 cm H2O; [SD: ±16.5]), 6 months (+18.6%;
mean: 31 cm H2O; ([SD: ±15]), and 9 months +12.9% (mean:
29.5 cm H2O; [SD: ±14.7]). However, there was no statistically signiﬁ-
cant improvement compared to baseline at 12 months +4.3% (mean:
27.2 cm H2O [13.8]) and at 24 months +1.9% (mean: 26.6 175 cm
H2O; [SD: ±14.2]) (Fig. 2). To check the real beneﬁt of Threshold train-
ing theMIP andMEP values were also taken in a period of 6 to 8 month
before the beginning of the study. In this period the patient were only
under enzyme treatment. The MIP mean was 33.2 cm H2O instead of
31.6 cmH2Oof the baseline values. These data are not statistically differ-
ent. Thismeans that theMIP andMEP values are stable before the begin-
ning of the study. FVCwas also evaluated. At baseline, the percentage of
the predicted value of FVC had a mean (SD) of 46.3%(SD: ±24.2). FVC
remained stable at 3 months (48.6%), 6 months (46.5%), 9 months
(45%), 12 months (44.6%) and 24 months (47.8%). There were no de-
tectable improvements during the study. (Fig. 3). Patients were
assessed for dyspnea grade and clinical examination using themodiﬁed
Gardner–Medwin–Walton scale for the grade of autonomy at baseline
and after each control visit. At baseline, the modiﬁed Gardner–
Medwin–Walton scale was between Grades 4 and 5. No modiﬁcation
of dyspnea symptoms was observed. Grade values remained stable
throughout the study.
4. Discussion
Our data show that respiratory muscle training with threshold pre-
serves and improves inspiratory muscle strength in patients with
LOPD. Some examples can be found in the literature for training rehabil-
itation with Threshold. In this study we observed that MIP signiﬁcantly
improved in our study population and this improvement appeared to
remain stable in the subsequent follow-up period. At the beginning of
the study some individual response are different, this can be explicate
with the adapting in training program and procedure for monitoring
pulmonary functional tests. This ﬁnding indicates that patient compli-
ance was reliable.
Decline in respiratory strength is themost important prognostic fac-
tor in patients with LOPD.
Natural progression of respiratory muscle weakness in Pompe dis-
ease in the absence of treatment has been estimated at a decrease of
3.2% in MIP per year [21]. ERT may itself stabilize respiratory function
[22,23]. However, we cannot assess the effect of the training alone
since all the patients were treated with ERT. Furthermore, evaluation
ofMEP showed a positive trend even though the patients did not under-
go speciﬁc training for these muscles. Our data conﬁrm a previous ob-
servation of two case reports by Jones et al. [11] who demonstrated a
favorable effect of speciﬁc individual respiratory muscle training for
several weeks in two patients. However, the patients in this study
were followed up to 24 months and the observed beneﬁts did not per-
sist during this period. MIP and MEP were chosen as the primary end-
Fig. 1.MIP mean values at baseline and after 3, 6, 9, 12 and 24 months of respiratory muscle strength training in late onset Pompe patients receiving ERT.
Fig. 2.MEP mean values at baseline and after 3, 6, 9, 12 and 24 months of respiratory muscle strength training in late onset Pompe patients receiving ERT.
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points because respiratory muscle training can cause an effect on these
outcomes as well as respiratory function. We found that respiratory
strength improvementmay last up to 24months and that FVC remained
stable during the study. No difference of dyspnea symptoms was ob-
served during the study. We showed that the increase of MIP and MEP
is very pronounced in the ﬁrst year with a slow decrease in the second
year of treatment, especially with MEP. The initial beneﬁt of increased
MEP can be attributed to different training effects. It is likely that during
exercise, expiratorymuscles are also stimulated. In LOPD, the thorax ex-
ercise allows for better expansion andmobility of the sternocostal joints
preventing their calciﬁcation andmuscle hypoextensibility/contracture.
Some patients presents different MIP and MEP trends at the beginning
of this study, one possible explication is that MIP and MEP maneuvers
are technique dependent and this can in part explicate this numbers.
The early decrease in MEP is presumably because the training with
Threshold operates only on inspiratory muscles. In addition, the pa-
tients remained at the same grade of autonomy measured by the mod-
iﬁed Gardner-Medwin-Walton scale. During the study no correlation
between the MIP values and the modiﬁed Gardner-Medwin-Walton
scale were observed. One of the major challenges encountered in this
study was the ability to assess the compliance of patients. Since it is a
rare disorder, patients usually have to travel to a specialized center in
order to be treated. In fact, only 1/8 patients were living in Trieste;
therefore, conducting interviews by telephone was the most appropri-
ate method to promote and evaluate training compliance. Adherence
to treatmentmay be negatively affected by the higher level of resistance
applied to the device, thus markedly increasing the intensity of work; it
may sometimes lead an effect that is difﬁcult to maintain. The training
was explicated into the hospital and the patients were formed to repeat
the same exercise at home. We have no certitude of the compliance of
exercise at home. Therefore, patients have to be systematically encour-
aged to continue the training protocol. Our data provide further insights
into the beneﬁcial, cost effective, and safe results of inspiratory muscle
training in Pompe disease. Since this is a rare disease, it would be difﬁ-
cult to conduct controlled studies. We believe that respiratory muscle
training should be established early in the treatment of this infrequent
but disabling condition. Traditionally, excessively strenuous resistance
exercises have been discouraged inmuscle disorders because of the po-
tential for exacerbating muscle lesion and degeneration. Studies evalu-
ating the effect of ERT in LOPD disease showed a favorable pattern of
response in muscle strength, including respiratory parameters, but fur-
ther studies are needed to conﬁrm these and our data.
5. Conclusion
Respiratorymuscle trainingwith threshold in combinationwith ERT
showed a positive effect on inspiratorymuscle strength in patients with
late-onset Pompe disease. We observed a signiﬁcant increase in
respiratory muscle strength in the ﬁrst year in our study population
and this improvement appeared to remain stable in the subsequent
follow-up period. A larger randomized controlled trial is needed to con-
ﬁrm these results.
5.1. Consent
Written informed consent was obtained from the patients and
patient's parents (in one case of non-adult patient) of kin for the publi-
cation of this report.
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